MARKET

SLS

SLS

Sellas Life Sciences Group Inc
NASDAQ
0.9285
+0.0085
+0.92%
Closed 19:59 01/14 EST
OPEN
0.9000
PREV CLOSE
0.9200
HIGH
0.9998
LOW
0.9000
VOLUME
752.52K
TURNOVER
0
52 WEEK HIGH
1.720
52 WEEK LOW
0.4986
MARKET CAP
65.35M
P/E (TTM)
-1.3054
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SLS last week (0106-0110)?
Weekly Report · 2d ago
Sellas Life Sciences announces key business objecives for 2025
TipRanks · 6d ago
SELLAS Outlines 2025 Objectives: Phase 3 REGAL Interim Analysis In January, Phase 2 SLS009 Topline Data And FDA Review Expected 1H 2025, Tambiciclib Named As INN For SLS009, Non-Dilutive Grant Funding Application Submitted For AML Expansion, And Pediatric Program Development Underway
Benzinga · 6d ago
SELLAS LIFE SCIENCES GROUP INC: FULL TOPLINE PHASE 2 DATA IN ACUTE MYELOID LEUKEMIA AND FDA REGULATORY REVIEW EXPECTED IN 1H 2025 FOR SLS009
Reuters · 6d ago
SELLAS Announces Key Business Objectives for 2025
Barchart · 01/08 07:20
Weekly Report: what happened at SLS last week (1230-0103)?
Weekly Report · 01/06 10:02
Weekly Report: what happened at SLS last week (1223-1227)?
Weekly Report · 12/30/2024 09:59
Weekly Report: what happened at SLS last week (1216-1220)?
Weekly Report · 12/23/2024 10:02
More
About SLS
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of novel therapeutics for a range of cancer indications. The Company's product candidates, galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9), inhibitor. GPS is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.

Webull offers Sellas Life Sciences Group Inc stock information, including NASDAQ: SLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLS stock methods without spending real money on the virtual paper trading platform.